Pantoprazol Hikma (Pantoprazole)

Pantoprazole, the active ingredient in Pantoprazol Hikma, is a proton pump inhibitor presented as an intravenous solution for intravenous use. It treats acid‑related disorders such as erosive esophagitis, gastric ulcer, duodenal ulcer and gastro‑oesophageal reflux disease in hospitalised patients. GNH USA supplies Pantoprazol Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Pantoprazol Hikma is a proton pump inhibitor used in the management of acid‑related gastrointestinal conditions. - Erosive esophagitis: promotes healing of the esophageal lining by reducing gastric acid exposure. - Gastric ulcer: supports ulcer resolution through sustained acid suppression. - Duodenal ulcer: facilitates ulcer healing by maintaining a low‑acid environment. - Gastro‑oesophageal reflux disease (GERD): alleviates heartburn and prevents reflux‑related mucosal damage.

Pantoprazol Hikma may be associated with a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild, transient headache reported in clinical use. - Diarrhoea: loose stools occurring during therapy. - Nausea: occasional feeling of queasiness. - Abdominal pain: mild discomfort in the stomach region. - Flatulence: increased intestinal gas. - Constipation: reduced bowel movements.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing. - Clostridioides difficile infection: severe diarrhoea linked to intestinal flora disruption. - Low magnesium levels (hypomagnesemia): muscle cramps, irregular heartbeat. - Liver enzyme elevation: increased ALT/AST indicating hepatic stress. - Acute interstitial nephritis: kidney inflammation presenting with fever and rash. - Bone fracture risk: long‑term use may affect bone density.

When using Pantoprazol Hikma, clinicians should consider several safety aspects. - Pregnancy: Category B – no proven risk in humans, but use only if clearly needed. - Breastfeeding: Small amounts pass into milk; weigh benefits against risks. - Renal impairment: Adjust monitoring; no dose reduction required but watch electrolytes. - Hepatic impairment: Use with caution; monitor liver function tests. - Concomitant use with drugs that require gastric acidity for absorption: May reduce effectiveness. - Store at ambient temperature: keep in original packaging, protect from moisture and light.

Pantoprazol Hikma can affect the pharmacokinetics of several co‑administered medicines.

Major Interactions (Avoid): - Ketoconazole oral suspension: reduced absorption due to increased gastric pH. - Atazanavir: markedly decreased plasma concentrations, risking therapeutic failure. - Clopidogrel: diminished activation leading to reduced antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: potential increase in INR, requiring more frequent coagulation monitoring. - Methotrexate: decreased renal clearance may raise serum levels. - Digoxin: slight rise in serum concentration; monitor for toxicity.